Published in AIDS Care on June 01, 2011
HIV-infected adolescents in southern Africa can achieve good treatment outcomes: results from a retrospective cohort study. AIDS (2013) 1.09
Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment. AIDS Behav (2013) 1.01
Assessing Problematic Substance Use in HIV Care: Which Questions Elicit Accurate Patient Disclosures? J Gen Intern Med (2016) 0.96
The unique challenges facing HIV-positive patients who smoke cigarettes: HIV viremia, ART adherence, engagement in HIV care, and concurrent substance use. AIDS Behav (2015) 0.91
HIV prevention in care and treatment settings: baseline risk behaviors among HIV patients in Kenya, Namibia, and Tanzania. PLoS One (2013) 0.90
Operationalizing treatment as prevention in Los Angeles County: antiretroviral therapy use and factors associated with unsuppressed viral load in the Ryan White system of care. AIDS Patient Care STDS (2012) 0.87
Intentional Medication Nonadherence Because of Interactive Toxicity Beliefs Among HIV-Positive Active Drug Users. J Acquir Immune Defic Syndr (2015) 0.86
Patterns of substance use among HIV-positive adults over 50: implications for treatment and medication adherence. Drug Alcohol Depend (2014) 0.85
Repeated cocaine treatment enhances HIV-1 Tat-induced cortical excitability via over-activation of L-type calcium channels. J Neuroimmune Pharmacol (2014) 0.85
Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants. AIDS Patient Care STDS (2015) 0.84
Relative Efficiency of Field and Online Strategies in the Recruitment of HIV-Positive Men Who Have Sex With Men. AIDS Educ Prev (2015) 0.84
Stimulant use patterns and HIV transmission risk among HIV-serodiscordant male couples. J Acquir Immune Defic Syndr (2015) 0.82
Substance Use and Adherence Among People Living with HIV/AIDS Receiving cART in Latin America. AIDS Behav (2016) 0.81
Direct and Indirect Effects of Heavy Alcohol Use on Clinical Outcomes in a Longitudinal Study of HIV Patients on ART. AIDS Behav (2016) 0.80
Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances. Neurobehav HIV Med (2012) 0.80
Pain is associated with risky drinking over time among HIV-infected persons in St. Petersburg, Russia. Drug Alcohol Depend (2014) 0.79
Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. Drug Alcohol Depend (2015) 0.76
Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study. Eur J Med Res (2011) 0.75
90-90-90-Plus: Maintaining Adherence to Antiretroviral Therapies. AIDS Patient Care STDS (2017) 0.75
Alcohol-antiretroviral interactive toxicity beliefs as a potential barrier to HIV pre-exposure prophylaxis among men who have sex with men. J Int AIDS Soc (2017) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med (2000) 23.10
Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry (2001) 7.30
Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med (2002) 5.30
A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med (2002) 4.49
Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr (2005) 3.92
Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med (2003) 3.81
Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr (2001) 3.67
Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS (2002) 3.45
Epidemiology of HIV/AIDS--United States, 1981-2005. MMWR Morb Mortal Wkly Rep (2006) 3.31
A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res (2005) 3.21
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19
Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs (2006) 2.89
Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol (2006) 2.81
Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis (1999) 2.57
Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.15
Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med (2001) 1.73
Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS (1990) 1.61
Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr (2004) 1.59
Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr (2003) 1.58
Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis (2004) 1.54
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (1999) 1.36
A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr (1999) 1.35
The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction (2005) 1.32
Effects of cigarette smoke and alcohol on ciliated tracheal epithelium and inflammatory cell recruitment. Am J Respir Cell Mol Biol (2006) 1.31
Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS (2008) 1.25
Illicit drug use and HIV treatment outcomes in a US cohort. AIDS (2008) 1.24
Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion. Epidemiology (1996) 1.21
Cocaine and sigma-1 receptors modulate HIV infection, chemokine receptors, and the HPA axis in the huPBL-SCID model. J Leukoc Biol (2005) 1.16
Cocaine-mediated enhancement of virus replication in macrophages: implications for human immunodeficiency virus-associated dementia. J Neurovirol (2007) 1.13
Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med (2000) 1.11
Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy. Brain Behav Immun (2008) 1.08
The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users. AIDS (1997) 1.04
Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084. AIDS Patient Care STDS (2008) 1.03
Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antivir Ther (2009) 1.03
Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS (1991) 1.00
Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in Acquired Immunodeficiency Syndrome. Clin Infect Dis (2002) 0.91
Personality profiles of normal healthy research volunteers: a potential concern for clinical drug trial investigators? Med Hypotheses (2005) 0.82
The effects of ethanol on mucociliary clearance. Alcohol Clin Exp Res (1985) 0.81
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med (2004) 6.87
The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc (2004) 6.64
Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet (2008) 4.66
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 4.57
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med (2009) 4.54
Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ (2013) 3.88
Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2009) 3.52
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol (2008) 3.36
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA (2006) 3.23
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol (2004) 3.12
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis (2008) 3.09
Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr (2010) 2.96
Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA (2006) 2.96
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 2.89
Characterization of phthalate exposure among pregnant women assessed by repeat air and urine samples. Environ Health Perspect (2008) 2.75
Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis (2012) 2.64
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64
Variability of urinary phthalate metabolite and bisphenol A concentrations before and during pregnancy. Environ Health Perspect (2012) 2.43
Polymorphisms in the mannose binding lectin-2 gene and acute respiratory distress syndrome. Crit Care Med (2007) 2.31
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol (2002) 2.28
Clinical implementation of full Monte Carlo dose calculation in proton beam therapy. Phys Med Biol (2008) 2.24
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS (2012) 2.19
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2004) 2.17
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis (2004) 2.17
Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS (2009) 2.16
An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf (2005) 2.15
Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis (2011) 2.15
Neurologic complications of HIV disease and their treatment. Top HIV Med (2010) 2.14
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis (2011) 2.12
Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol (2003) 2.07
Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis (2007) 2.05
Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis (2003) 2.04
AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials (2008) 1.99
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS (2003) 1.99
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Predictors and variability of urinary paraben concentrations in men and women, including before and during pregnancy. Environ Health Perspect (2012) 1.96
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med (2004) 1.89
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis (2007) 1.89
Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting. J Acquir Immune Defic Syndr (2010) 1.83
Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection. Pediatrics (2009) 1.79
Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS (2002) 1.78
A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr (2007) 1.76
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med (2014) 1.75
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS (2004) 1.74
Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations. PLoS One (2013) 1.74
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol (2011) 1.73
The association of particulate air metal concentrations with heart rate variability. Environ Health Perspect (2002) 1.71
Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol (2004) 1.65
Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol (2005) 1.62
Energy imbalance and the risk of overfeeding in critically ill children. Pediatr Crit Care Med (2011) 1.61
Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis (2008) 1.60
Gender differences in health-related quality of life in patients with HIV/AIDS. Qual Life Res (2005) 1.60
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain (2006) 1.60
Serum concentrations of polychlorinated biphenyls in relation to in vitro fertilization outcomes. Environ Health Perspect (2011) 1.60
NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine. Birth Defects Res B Dev Reprod Toxicol (2004) 1.57
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord (2007) 1.56
The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS (2005) 1.55
Long-term outcomes of infants and children undergoing percutaneous endoscopy gastrostomy tube placement. J Pediatr Gastroenterol Nutr (2013) 1.55
Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis (2004) 1.54
Plasma C-reactive protein in early pregnancy and preterm delivery. Am J Epidemiol (2005) 1.53
Mental health functioning among children and adolescents with perinatal HIV infection and perinatal HIV exposure. AIDS Care (2011) 1.51
Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis (2010) 1.51
Urinary bisphenol A concentrations and early reproductive health outcomes among women undergoing IVF. Hum Reprod (2012) 1.48
Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol (2002) 1.48
Maternal urinary metabolites of Di-(2-Ethylhexyl) phthalate in relation to the timing of labor in a US multicenter pregnancy cohort study. Am J Epidemiol (2009) 1.47
Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr (2005) 1.47
Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr (2008) 1.46
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 1.43
Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A (2011) 1.42
Challenges in using observational studies to evaluate adverse effects of treatment. N Engl J Med (2007) 1.42
Impact of HIV severity on cognitive and adaptive functioning during childhood and adolescence. Pediatr Infect Dis J (2012) 1.41
Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin Infect Dis (2005) 1.40
HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis (2010) 1.40
Good agreement between endoscopic findings and biopsy reports supports limited tissue sampling during pediatric colonoscopy. J Pediatr Gastroenterol Nutr (2014) 1.39
Genetic modification of the association between peripubertal dioxin exposure and pubertal onset in a cohort of Russian boys. Environ Health Perspect (2012) 1.39
The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS (2002) 1.38
The association between personal measurements of environmental exposure to particulates and heart rate variability. Epidemiology (2002) 1.38
Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis (2002) 1.38